Skip to main content
. 2019 Feb 15;19(1):83–91. doi: 10.5230/jgc.2019.19.e4

Table 1. Clinicopathological characteristics.

Characteristics All Patients After propensity matching
LDG (n=60) ODG (n=228) P-value LDG (n=60) ODG (n=60) P-value
Sex 0.553 0.700
Male 38 (63.3%) 156 (68.4%) 38 (63.3%) 41 (68.3%)
Female 22 (36.7%) 72 (31.6%) 22 (36.7%) 19 (31.7%)
Age (yr) 62.5±14.2 61.4±12.7 0.561 62.5±14.2 62.4±10.4 0.965
BMI (kg/m2) 24.3±4.3 23.3±3.1 0.096 24.3±4.3 24.1±3.5 0.707
ASA score 0.083 0.481
1 4 (6.7%) 12 (5.3%) 4 (6.7%) 6 (10.0%)
2 51 (85.0%) 163 (71.5%) 51 (85.0%) 45 (75.0%)
3 5 (8.3%) 51 (22.4%) 5 (8.3%) 8 (13.3%)
4 0 (0.0%) 2 (0.9%) 0 (0.0%) 1 (1.7%)
Clinical staging according to AJCC/UICC 7th edition <0.001 0.621
IB 22 (36.7%) 28 (12.3%) 22 (36.7%) 17 (28.3%)
II 29 (48.3%) 115 (50.4%) 29 (48.3%) 33 (55.0%)
III 9 (15.0%) 85 (37.3%) 9 (15.0%) 10 (16.7%)
Pathological staging according to AJCC/UICC 7th edition 0.647 0.696
IIA 25 (41.7%) 72 (31.6%) 25 (41.7%) 22 (36.7%)
IIB 12 (20.0%) 48 (21.1%) 12 (20.0%) 16 (26.7%)
IIIA 9 (15.0%) 44 (19.3%) 9 (15.0%) 10 (16.7%)
IIIB 10 (16.7%) 42 (18.4%) 10 (16.7%) 6 (10.0%)
IIIC 4 (6.7%) 22 (9.6%) 4 (6.7%) 6 (10.0%)
Histology 1.000 0.451
Differentiated 20 (33.3%) 74 (32.5%) 20 (33.3%) 25 (41.7%)
Undifferentiated 40 (66.7%) 154 (67.5%) 40 (66.7%) 35 (58.3%)
Tumor size (cm) 4.6±2.7 5.7±2.2 0.001 4.6±2.7 4.5±1.6 0.808
Adjuvant chemotherapy 0.087 0.708
No 22 (36.7%) 56 (24.6%) 22 (36.7%) 25 (41.7%)
Yes 38 (63.3%) 172 (75.4%) 38 (63.3%) 35 (58.3%)
Follow-up (mo) 38.5±22.8 40.3±28.5 0.608 38.5±22.8 38.5±30.8 0.997

LDG = laparoscopic distal gastrectomy; ODG = open distal gastrectomy; BMI = body mass index; ASA = American Society of Anesthesiologists; AJCC/UICC = American Joint Committee on Cancer/Union for International Cancer Control.